Across 6 studies, all reported beneficial effects of Lactobacillus acidophilus L-92 on reducing atopic dermatitis severity, with 4 showing statistically significant findings. The predominant effect size is moderate, and evidence is strongest in children and adult clinical populations. Dose information is limited, with only one study specifying a heat-killed and dried L-92 daily regimen.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). The evidence base is small (only 6 studies) — conclusions should be considered preliminary. Most studies did not report dose or form details, limiting applicability for specific product recommendations.
No adverse events were reported during the study period.
from: Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with aThe treatment significantly reduced SCORAD score (WMD = -3.75, 95% CI: -5.08 to -2.42).
Compared with the placebo group, the L-92 group showed significant decreases in investigator global assessment, eczema area and severity index, and scoring atopic dermatitis.
Pooled analysis using a random-effects model (Hedges' g ≈ 0.65, p < 0.05) indicated a moderate to large improvement in AD severity with probiotic therapy.
Orally administered L-92 significantly ameliorated the symptoms of AD in Japanese children.
Lactobacillus acidophilus L-92 has been reported to improve clinical symptoms in patients with atopic dermatitis.
Studies suggest that L. acidophilus L-92 may help alleviate atopic dermatitis, contributing to improved skin condition and quality of life.